Clinical-stage biopharmaceutical company Adocia (Euronext Paris:ADOC) announced on Tuesday that it has filed patent applications for stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone platform.

These combinations, such as CagriSema (cagrilintide and semaglutide), can be administered using standard injection devices, offering convenience and flexibility for patients.

Adocia's innovation addresses the challenge of combining different hormones for more effective obesity treatments. By overcoming compatibility issues, Adocia's BioChaperone platform enables the production of stable formulations that can be administered using existing injection devices. This could significantly improve the accessibility and convenience of these treatments.

Adocia is also researching new peptide combinations for obesity treatment and exploring partnerships to advance these innovations.